Clinical Trial

The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE: blood clots in the legs or lungs) for postpartum individuals with VTE risk factors.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-07-28
notable Trial sites expanded: 3 -> 12 locations 2026-07-28
notable Primary completion pushed: 2030-08 -> 2030-09 2026-07-28
Trial Details
NCT Number NCT06494878
Lead Sponsor University of Calgary
Collaborators: Canadian Institutes of Health Research (CIHR), European Clinical Research Infrastructure Network
Conditions Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin
Enrollment 8,805 participants
Start Date 2026-06-04
Primary Completion 2030-09 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-27